Related Experiment Video
Updated: Aug 20, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Insights
Verapamil effectively terminates supraventricular tachycardia and manages atrial fibrillation and flutter. This calcium channel blocker is a primary treatment for various tachyarrhythmias, offering significant clinical benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Verapamil's antiarrhythmic properties were recognized prior to its identification as a calcium ion-antagonist.
- Calcium channel blockers play a crucial role in managing cardiac arrhythmias.
Purpose of the Study:
- To review the antiarrhythmic effects of verapamil.
- To highlight verapamil's efficacy in different supraventricular and ventricular tachyarrhythmias.
Main Methods:
- Clinical observations and established data on verapamil's use in treating tachyarrhythmias.
- Review of pharmacological actions and clinical outcomes.
Main Results:
- Intravenous verapamil effectively terminates paroxysmal reciprocating atrioventricular tachycardia.
- Verapamil consistently slows ventricular response in atrial fibrillation and increases AV-nodal block in atrial flutter.
- Oral verapamil is beneficial for prophylaxis of atrioventricular reentry tachycardia and modulating atrial fibrillation.
Conclusions:
- Verapamil is the preferred agent for terminating paroxysmal supraventricular tachycardia.
- It demonstrates significant utility in managing atrial fibrillation and flutter, with specific applications in ventricular tachycardia.
- Verapamil's role as a calcium ion-antagonist underpins its broad antiarrhythmic actions.
Abstract:
The antiarrhythmic effects of verapamil were observed before it was appreciated that it was a calcium ion-antagonist. Intravenous verapamil is highly effective in the termination of paroxysmal reciprocating atrioventricular tachycardia, whether associated with preexcitation or involving the atrioventricular node alone. It consistently slows and regularises the ventricular response in atrial fibrillation, and usually increases the degree of AV-nodal block in atrial flutter though it occasionally induces a return to sinus rhythm. Given orally it is useful for the prophylaxis of atrioventricular reentry tachycardia, and also in modulating the atrioventricular nodal response in atrial fibrillation. Favourable response in ventricular tachycardia is exceptional and then seen in specific benign varieties. Verapamil is the agent of choice for the termination of paroxysmal supraventricular tachycardia.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

